Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin for advanced hepatocellular carcinoma (HCC-Rap-001)
2004-002834-20Phase 2Completed
- Sponsor
- Medical University of Vienna, Department of Internal Medicine IV
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in hepatocellular carcinoma (HCC), sponsored by Medical University of Vienna, Department of Internal Medicine IV. Primary endpoints: Side effects, Response rate and 4 more. Started Jan 2008; status: completed.
02
Drugs
sirolimus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2004-002834-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002834-20.